$0.01
46.67%
Nasdaq, Fri, Dec 27 2024
ISIN
US0909112072
Symbol
BIOL

BIOLASE, Inc. Stock price

$0.01
+0.01 120.00% 1M
-0.07 85.53% 6M
-1.11 99.02% YTD
-1.15 99.05% 1Y
-1,062.49 100.00% 3Y
-1,224.49 100.00% 5Y
-33,624.99 100.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.00 46.67%
ISIN
US0909112072
Symbol
BIOL
Sector

Key metrics

Market capitalization $400.00k
Enterprise Value $14.42m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.31
P/S ratio (TTM) P/S ratio 0.01
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -7.44%
Revenue (TTM) Revenue $46.03m
EBIT (operating result TTM) EBIT $-13.52m
Free Cash Flow (TTM) Free Cash Flow $-13.68m
Cash position $3.44m
EPS (TTM) EPS $-7.85
P/E forward negative
P/S forward 0.00
EV/Sales forward 0.25
Short interest 5.00%
Show more

Is BIOLASE, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

BIOLASE, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast BIOLASE, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast BIOLASE, Inc.:

Buy
100%

Financial data from BIOLASE, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
46 46
7% 7%
100%
- Direct Costs 30 30
8% 8%
66%
16 16
6% 6%
34%
- Selling and Administrative Expenses 22 22
26% 26%
47%
- Research and Development Expense 4.92 4.92
24% 24%
11%
-11 -11
43% 43%
-24%
- Depreciation and Amortization 2.62 2.62
16% 16%
6%
EBIT (Operating Income) EBIT -14 -14
37% 37%
-29%
Net Profit -16 -16
36% 36%
-35%

In millions USD.

Don't miss a Thing! We will send you all news about BIOLASE, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BIOLASE, Inc. Stock News

Neutral
Accesswire
3 months ago
LAKE FOREST, CA / ACCESSWIRE / October 1, 2024 / BIOLASE, Inc. (NASDAQ:BIOL) (the "Company"), a global leader in dental lasers, today announced that the Company and its direct domestic subsidiaries have voluntarily initiated Chapter 11 proceedings (the "Bankruptcy Petitions") in the United States Bankruptcy Court for the District of Delaware (the "Court"). BIOLASE will seek Court approval to co...
Neutral
Accesswire
5 months ago
LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024. "We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive...

Company Profile

BIOLASE, Inc. is a medical device company, which engages in developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems uses a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems performs soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Irvine, CA.

Head office United States
CEO John Beaver
Employees 157
Founded 1987
Website www.biolase.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today